Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000664649 | SCV000788649 | uncertain significance | Alstrom syndrome | 2017-01-31 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000664649 | SCV001013258 | likely benign | Alstrom syndrome | 2024-01-02 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000664649 | SCV001781464 | uncertain significance | Alstrom syndrome | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001576145 | SCV001803274 | likely benign | not provided | 2018-11-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002360690 | SCV002660634 | likely benign | Cardiovascular phenotype | 2020-11-22 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV001576145 | SCV004155013 | likely benign | not provided | 2024-05-01 | criteria provided, single submitter | clinical testing | ALMS1: BP4, BP7 |
Natera, |
RCV000664649 | SCV001455033 | likely benign | Alstrom syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |